Business

22nd Century Group to Announce Fourth Quarter 2023 Results on March 28, 2024

Mocksville, North Carolina--(Newsfile Corp. - March 15, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco company focused on tobacco harm reduction

article22nd Century Group, IncMarch 15, 20243/company/22nd-century-group-inc/news/22nd-century-group-to-announce-fourth-quarter-2023-results-on-march-28-2024
22nd Century Group to Announce Fourth Quarter 2023 Results on March 28, 2024

About this update from 22nd Century Group, Inc

[{"type":"text","content":"Mocksville, North Carolina--(Newsfile Corp. - March 15, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco company focused on tobacco harm reduction to improve smoker health and wellness, will host a live webcast on Thursday, March 28, 2024, at 8:00 AM ET to discuss its 2023 fourth quarter results, which are to be reported in a press release at 6:00 AM ET the same day.\nDuring the webcast, Larry Firestone, chairman and chief executive officer, and Hugh Kinsman, chief financial officer, will review financial results and discuss progress made in the recent months.\nFollowing management's prepared remarks and slide presentation, the Company will host a Q&A session, during which management will accept questions from research analysts.\nThe live and archived webcast and slide presentation will be accessible on the Events web page in the Company's Investor Relations section of the website, at https://ir.xxiicentury.com/events-and-presentations. Please access the website at least 15 minutes prior to the start of the webcast to register and, if necessary, download and install any required software.\nAbout 22nd Century Group, Inc.22nd Century Group, Inc. (NASDAQ: XXII) is a tobacco company focused on tobacco harm reduction, reduced nicotine tobacco and improving smoker health and wellness. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.\nLearn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.\nLearn more about VLN® at tryvln.com.\nCautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained ...

More updates from 22nd Century Group, Inc